{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:45:23Z","timestamp":1791639923320,"version":"4.3.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK090728"],"award-info":[{"award-number":["P30 DK090728"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Intracranial aneurysm rupture is the most devastating complication of autosomal dominant polycystic kidney disease. Whether selective or widespread intracranial aneurysm screening is indicated remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants &amp; measurements<\/jats:title>\n                    <jats:p>Records of 3010 patients with autosomal dominant polycystic kidney disease evaluated at the Mayo Clinic between 1989 and 2017 were reviewed. Those who had presymptomatic magnetic resonance angiography screening were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety-four intracranial aneurysms were diagnosed in 75 of 812 (9%) patients who underwent magnetic resonance angiography screening. Sex, age, race, and genotype were similar in the groups with and without aneurysms; hypertension and history of smoking were more frequent in the aneurysm group. Twenty-nine percent of patients with aneurysms compared with 11% of those without aneurysms had a family history of subarachnoid hemorrhage (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Most aneurysms were small (median diameter =4 mm; range, 2\u201312 mm); 85% were in the anterior circulation. During a total imaging follow-up of 469 patient-years,\n                      <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                      intracranial aneurysms were detected in five patients; eight intracranial aneurysms grew (median =2 mm; range, 1\u20133 mm). During a total clinical follow-up of 668 patient-years, seven patients had preemptive clipping or coil embolization; no intracranial aneurysms ruptured. During a total clinical follow-up of 4783 patient-years in 737 patients with no intracranial aneurysm detected on the first magnetic resonance angiography screening, two patients had an intracranial aneurysm rupture (0.04 per 100 person-years; 95% confidence interval, 0 to 0.10). The rate of intracranial aneurysm rupture in large clinical trials of autosomal dominant polycystic kidney disease was 0.04 per 100 patient-years (95% confidence interval, 0.01 to 0.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intracranial aneurysms were detected by presymptomatic screening in 9% of patients with autosomal dominant polycystic kidney disease, more frequently in those with familial history of subarachnoid hemorrhage, hypertension, or smoking. None of the patients with and two of the patients without aneurysm detection on screening suffered aneurysmal ruptures. The overall rupture rate in our autosomal dominant polycystic kidney disease cohort was approximately five times higher than that in the general population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.14691218","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T15:44:05Z","timestamp":1564501445000},"page":"1151-1160","source":"Crossref","is-referenced-by-count":72,"title":["Presymptomatic Screening for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"14","author":[{"given":"Irina M.","family":"Sanchis","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehbaz","family":"Shukoor","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Irazabal","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Madsen","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad T.","family":"Chebib","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Hogan","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8734-9699","authenticated-orcid":false,"given":"Ziad","family":"El-Zoghby","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Huston","sequence":"additional","affiliation":[{"name":"Radiology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Brown","sequence":"additional","affiliation":[{"name":"Neurology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and Departments of"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2215\/CJN.09731110","article-title":"Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.","volume":"6","author":"Irazabal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.kint.2017.08.016","article-title":"Screening for intracranial aneurysms in autosomal dominant polycystic kidney disease is cost-effective.","volume":"93","author":"Flahault","year":"2018","journal-title":"Kidney Int"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1681\/ASN.2006121387","article-title":"Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.","volume":"18","author":"Rossetti","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease.","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1681\/ASN.V131269","article-title":"Management of cerebral aneurysms in autosomal dominant polycystic kidney disease.","volume":"13","author":"Pirson","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease.","volume":"11","author":"Perrone","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nrneurol.2017.14","article-title":"Unruptured intracranial aneurysms: Development, rupture and preventive management.","volume":"13","author":"Etminan","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1017\/S0317167100017984","article-title":"Unruptured intracranial aneurysms: Some questions answered, many questions remain. Re: Pelz D. CURES and the dilemma of unruptured intracranial aneurysms. Can J Neuro Sci. 2011 Mar;38(2):191-2.","volume":"38","author":"Brown","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0140-6736(16)30668-7","article-title":"Spontaneous subarachnoid haemorrhage.","volume":"389","author":"Macdonald","year":"2017","journal-title":"Lancet"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bmj.311.7000.288","article-title":"Subarachnoid haemorrhage in first and second degree relatives of patients with subarachnoid haemorrhage.","volume":"311","author":"Bromberg","year":"1995","journal-title":"BMJ"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199812103392401","article-title":"Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(03)13860-3","article-title":"Unruptured intracranial aneurysms: Natural history, clinical outcome, and risks of surgical and endovascular treatment.","volume":"362","author":"Wiebers","year":"2003","journal-title":"Lancet"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3171\/jns.2000.93.3.0379","article-title":"Natural history of unruptured intracranial aneurysms: Probability of and risk factors for aneurysm rupture.","volume":"93","author":"Juvela","year":"2000","journal-title":"J Neurosurg"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1056\/NEJMoa1113260","article-title":"The natural course of unruptured cerebral aneurysms in a Japanese cohort.","volume":"366","author":"Morita","year":"2012","journal-title":"N Engl J Med"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1474-4422(13)70263-1","article-title":"Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: A pooled analysis of six prospective cohort studies.","volume":"13","author":"Greving","year":"2014","journal-title":"Lancet Neurol"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1681\/ASN.V3188","article-title":"Saccular intracranial aneurysms in autosomal dominant polycystic kidney disease.","volume":"3","author":"Schievink","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1212\/WNL.30.10.1034","article-title":"The unchanging pattern of subarachnoid hemorrhage in a community.","volume":"30","author":"Phillips","year":"1980","journal-title":"Neurology"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/STROKEAHA.110.578740","article-title":"Screening for intracranial aneurysm in 355 patients with autosomal-dominant polycystic kidney disease.","volume":"42","author":"Xu","year":"2011","journal-title":"Stroke"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/01.ASN.0000118527.74850.66","article-title":"Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: A prospective ten-year follow-up.","volume":"15","author":"Schrier","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease.","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 trial.","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease.","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease.","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease.","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): A randomised, placebo-controlled, multicentre trial.","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: The DIPAK 1 randomized clinical trial.","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00701-018-3472-5","article-title":"Risk of de novo aneurysm formation in patients with unruptured intracranial aneurysms.","volume":"160","author":"Giordan","year":"2018","journal-title":"Acta Neurochir (Wien)"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1161\/STR.0000000000000070","article-title":"Guidelines for the management of patients with unruptured intracranial aneurysms: A guideline for healthcare professionals from the American Heart Association\/American Stroke Association.","volume":"46","author":"Thompson","year":"2015","journal-title":"Stroke"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/neuros\/nyx226","article-title":"Aneurysm morphology and prediction of rupture: An international study of unruptured intracranial aneurysms analysis.","volume":"82","author":"Mocco","year":"2018","journal-title":"Neurosurgery"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3174\/ajnr.A4490","article-title":"Autosomal dominant polycystic kidney disease and intracranial aneurysms: Is there an increased risk of treatment?","volume":"37","author":"Rozenfeld","year":"2016","journal-title":"AJNR Am J Neuroradiol"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/STROKEAHA.117.019972","article-title":"Lipid-lowering agents and high HDL (High-Density Lipoprotein) are inversely associated with intracranial aneurysm rupture.","volume":"49","author":"Can","year":"2018","journal-title":"Stroke"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/jnnp.2007.117655","article-title":"Incidence of subarachnoid haemorrhage: A systematic review with emphasis on region, age, gender and time trends.","volume":"78","author":"de Rooij","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201908000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:38:20Z","timestamp":1786369100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201908000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.14691218","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]}}}